Evidence map›Paper›PMID 39923753›Full record

ArticleTransfusion medicine (Oxford, England)2025

Universal new blood cell elution method with extensive phenotyping.

Lorraine Caruccio, Karen Byrne, David F Stroncek

Abstract read
In one paragraph

Article in Transfusion medicine (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lorraine CaruccioPathology and Laboratory Medicine, VA San Diego Healthcare System, San Diego, California, USA.ORCID https://orcid.org/0000-0002-0754-097X
Karen ByrneDepartment of Transfusion Medicine, National Institutes of Health, Clinical Center, Bethesda, Maryland, USA.
David F StroncekDepartment of Transfusion Medicine, National Institutes of Health, Clinical Center, Bethesda, Maryland, USA.

Funding

Structure Function of Granulocyte AntigensZ01CL002095 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID FRANK · 1997 to 2008
$81k
Intramural NIH HHS Z01 CL002095Intramural research program of the Clinical Center of National Institutes of Health
6 · The paper itself

Abstract

BACKGROUND/

objectivesNo erythrocyte elution method developed is uniformly successful or allows elution/phenotyping together. We previously developed an elution method using deionised formamide. We modified it to be universal for various cell types and call it modified formamide-method (Fm-method). It also preserves cells for phenotyping after elution. MATERIALS AND

methodsFm-method reagent contains deionised formamide, buffered high salt, EDTA, TE. Elution-reagent is removed by column centrifugation. Blood samples were used for development and validation. Results compared to commercial/common antibody elution/phenotyping methods.

resultsFm-method eluted antibodies, complement, other proteins, and nucleic acids and works with erythrocytes, leukocytes, other cells. It worked better than commercial kits used for elution/phenotyping with no false positives/negatives. It did not denature Kell and Lewis antigens and could be repeated as needed on samples to recover more antibodies and clean cells for phenotyping. Western blotting, PAGE and FCM demonstrated eluted proteins were not degraded and cells remained intact.

conclusionFm-method is excellent for elution and phenotyping and permits elution and phenotyping with one method and sample. It is useful for studies of various bound molecules and cell surface structures. It should be possible to elute various simple and complex carbohydrates as well. The Fm-method is efficient, inexpensive, scalable, uses common reagents. It should have excellent applications in various clinical, research, commercial settings.

Indexed as

ErythrocytesImmunophenotypingHumansPhenotypeantibodiesantigenselutionphenotypingRBCsWBCs

Identifiers

PMID39923753
PMCPMC11999790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.